CCM BioSciences at a Glance
•CCM Biosciences is funded by Chakrabarti Capital Management (CCM), an evergreen fund
with a focus on start-up stage biotech companies
•CCM’s corporate limited partner is PMC Group, Inc., a global chemical and pharmaceutical
conglomerate with 25+ year track record in chemicals/pharmaceuticals investment
management, the Chakrabarti family’s holdings have ~$1.5B equity value and are 100%
owned by the family.
•CCM Biosciences, the company building division of the holdings, has assembled a portfolio
of disruptive pharmaceutical assets many of which are first-in-class or best-in-class drug
programs, housed under 6 divisions
•The assets originate from in-house development and co-development with leading
academic institutions
•The pipeline spans precision oncology, autoimmune disorders and chronic, age-related
diseases and modalities and includes small molecules, biologics and nano-medicines
•CCM Biosciences has access to expert pharmaceutical development capabilities from the
PMC Group’s CRDMO division providing an agile and cost-effective development model.